Komori
Earnings presentation4588Oncolys BioPharma Inc.Pharmaceuticals

Interim Financial Results Briefing Materials

In the first half of the fiscal year ending December 2026, revenue increased and losses at each profit level narrowed, due to milestone revenue associated with manufacturing and marketing approval for Telomelysin and lower research and development expenses. Meanwhile, the Company withheld its full-year earnings forecast while reviewing its sales projections.

Worth reading
44Recurring
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
551
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Earnings presentationSecond quarter (interim period) of the fiscal year ending December 20263 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥503 million
Operating profit¥-767 million
Ordinary income¥-760 million
Net income¥-762 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Revenue increase¥475 million
  • Improvement in operating loss¥500 million
  • Decrease in R&D expenses¥251 million
  • Improvement in ordinary loss¥551 million
  • Improvement in net loss¥551 million
New initiatives
  • Telomelysin launch on 21 August 2026
  • OBP-301 Phase 1b/2a pilot trial for lower rectal cancer and anal gland cancer
  • Overseas expansion of OBP-301 and a new contract with one overseas company during the year
  • New marketing partnership for OBP-301
  • Investigator-initiated Phase 1 trial of OBP-702 for pancreatic cancer
Key KPIsA metric the company considers important as a management benchmark.
  • Telomelysin drug priceApproximately ¥3.1 million/vial
  • One-course drug priceApproximately ¥9.3 million
  • Number of new esophageal cancer patientsApproximately 25,000 people/year
  • Number of cases treated with radiation therapy aloneAt least 1,500 cases annually
  • Number of promotional facilities at launchApproximately 80
  • Number of promotional facilities after expansionMore than 300
  • Expected funding amount for OBP-601$20M to $30M
  • Funding from the Alzheimer's Drug Discovery Foundation$500 10,000
  • Award for longevity and healthy life expectancy extension research$2,200 10,000
  • Annual trading value turnover9.44、10.02、10.88、11.10、11.87、12.22、12.30
  • Market capitalization of the freely tradable shares477.4、550.7、518.5、653.8、660.8、701.2、639.8、579.4
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending December 2026
Net Sales¥503 million
Operating profit¥-767 million
Ordinary income¥-760 million
Net income¥-762 million
Breakdown of Factors Affecting the ChangeFactors Revenue increase / Amount ¥475 million, Factors Improvement in operating loss / Amount ¥500 million, Factors Decrease in R&D expenses / Amount ¥251 million, Factors Improvement in ordinary loss / Amount ¥551 million, Factors Improvement in net loss / Amount ¥551 million
Key KPIsIndicator name Telomelysin drug price / Value Approximately ¥3.1 million/vial / Year on year against the same period last year Not disclosed, Indicator name One-course drug price / Value Approximately ¥9.3 million / Year on year against the same period last year Not disclosed, Indicator name Number of new esophageal cancer patients / Value Approximately 25,000 people/year / Year on year against the same period last year Not disclosed, Indicator name Number of cases treated with radiation therapy alone / Value At least 1,500 cases annually / Year on year against the same period last year Not disclosed, Indicator name Number of promotional facilities at launch / Value Approximately 80 / Year on year against the same period last year Not disclosed, Indicator name Number of promotional facilities after expansion / Value More than 300 / Year on year against the same period last year Not disclosed, Indicator name Expected funding amount for OBP-601 / Value $20M to $30M / Year on year against the same period last year Not disclosed, Indicator name Funding from the Alzheimer's Drug Discovery Foundation / Value $500 10,000 / Year on year against the same period last year Not disclosed, Indicator name Award for longevity and healthy life expectancy extension research / Value $2,200 10,000 / Year on year against the same period last year Not disclosed, Indicator name Annual trading value turnover / Value 9.44、10.02、10.88、11.10、11.87、12.22、12.30 / Year on year against the same period last year Not disclosed, Indicator name Market capitalization of the freely tradable shares / Value 477.4、550.7、518.5、653.8、660.8、701.2、639.8、579.4 / Year on year against the same period last year Not disclosed
New initiativesTelomelysin launch on 21 August 2026, OBP-301 Phase 1b/2a pilot trial for lower rectal cancer and anal gland cancer, Overseas expansion of OBP-301 and a new contract with one overseas company during the year, New marketing partnership for OBP-301, Investigator-initiated Phase 1 trial of OBP-702 for pancreatic cancer
Items this document does not state (22)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company received milestone revenue associated with manufacturing and marketing approval, research and development expenses decreased by ¥251 million due to lower OBP-301 manufacturing process development costs, and foreign exchange gains and other items were recorded in addition to the reduction in operating loss.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Interim Financial Results Briefing Materials | Oncolys BioPharma Inc. (4588) timely disclosure | Komori